Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pain relief supplement no Tylenol, NAD says

This article was originally published in The Tan Sheet

Executive Summary

U.S. firm EuroPharma markets supplement Curamin as a fast-acting analgesic pain reliever like Tylenol and Advil, but the product can "at best" provide some pain relief over time and is not "fast acting" as ads suggest, the National Advertising Division says Oct. 19. The Council of Better Business Bureaus unit brought the challenge itself, under its work supported by a Council for Responsible Nutrition grant, and recommends EuroPharma modify or discontinue certain claims for Curamin, including that it "relieves pain fast and effective" and that users can "experience better relief than ever before." EuroPharma based the claims on tests comparing the product's curcumin and boswellia ingredients to those found in OTC analgesics. However, NAD determined "there was no evidence that Curamin is either 'fast-acting' or offers 'quick results starting with day one.'" NAD recommends the firm discontinue all "fast relief" claims and others suggesting the product provides "unprecedented levels" of relief. The Green Bay, Wis., firm agreed to modify ads to more accurately reflect its studies

You may also be interested in...

Ultra Botanica Needs Larger Studies For Curcumin Bioavailability Claims – NAD

Ultra Botanica’s supporting research relied on human studies with one to three participants and mice studies without direct comparisons to competing products.

Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings

Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts